Antithrombotic therapy following transcatheter aortic valve implantation: What challenge do we face?

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 3, 2016, Pages 381-389

  Barbanti, Marco ^a   Gulino, Simona ^a   Tamburino, Corrado ^a,b   Capodanno, Davide ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b ETNA Foundation   (Italy)

Author keywords

anticoagulant therapy; antiplatelet therapy; aspirin; bivalirudin; bleeding; clopidogrel; TAVI

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT;

ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; CONSENSUS; EMBOLISM; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEX DIFFERENCE; TRANSCATHETER AORTIC VALVE IMPLANTATION; ADVERSE EFFECTS; HEMORRHAGE; PROCEDURES; STROKE;

FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; STROKE; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84959133584     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2016.1124760     Document Type: Review

References (53)

1. Rodés-Cabau J. Transcatheter aortic valve implantation: current and future approaches. Nat Rev Cardiol. 2012; 9: 15-29.
2. Masson J-B, Kovac J, Schuler G, et al. Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications. J Am Coll Cardiol Intv. 2009; 2: 811-820.
3. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012; 366: 1705-1715.
4. Linke A, Gerckens U, Wenaweser P, et al. Treatment of high risk aortic stenosis patients with transcatheter Medtronic CoreValve implantation: results from the international multicenter ADVANCE study. J Am Coll Cardiol. 2012; 59: e8.
5. Moat NE, Ludman P, De Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) registry. JACC. 2011; 58: 2130-2138.
6. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011; 364: 2187-2198.
7. Généreux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using Valve Academic Research Consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol. 2012; 59: 2317.
8. Gurvitch R, Toggweiler S, Willson AB, et al. Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines. EuroIntervention. 2011; 7: 41-48.
9. Genereux P, Kodali S, Leon MB, et al. Clinical outcomes using a new crossover balloon occlusion technique for percutaneous closure after transfemoral aortic valve implantation. J Am Coll Cardiol Intv. 2011; 4: 861-867.
10. Nuis RJ, Rodés-Cabau J, Sinning JM, et al. Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2012; 5: 680-688.
11. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012; 366: 1686-1695.
12. Halliday BP, Dworakowski R, Brickham B, et al. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol. 2012; 109: 724-728.
13. Van Mieghem NM, Tchetche D, Chieffo A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol. 2012; 110: 1361-1367.
14. Ussia GP, Barbanti M, Petronio AS, et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur Heart J. 2012; 33: 969-976.
15. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart. 2013; 99: 860-865.
16. Messika-Zeitoun D, Aubry M-C, Detaint D, et al. Evaluation and clinical implications of aortic valve calcification measured by electronbeam computed tomography. Circulation. 2004; 110: 356-362.
17. Miller DC, Blackstone EH, Mack MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg. 2012; 143: 832-843.
18. Stortecky S, Windecker S, Pilgrim T, et al. Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention. 2012; 8: 62-70.
19. Ghanem A, Müller A, Nähle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol. 2010; 55: 1427-1432.
20. Hynes BG, Rodés-Cabau J. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art. Ann N Y Acad Sci. 2012; 1254: 151-163.
21. Stortecky S, Windecker S. Stroke: an infrequent but devastating complication in cardiovascular interventions. Circulation. 2012;126:2921-2924.
22. Tay ELW, Gurvitch R, Wijesinghe N, et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. J Am Coll Cardiol Intv. 2011; 4: 1290-1297.
23. Rodés-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol. 2013; 62: 2349-2359.
24. Bernelli C, Chieffo A, Montorfano M, et al. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2014; 7: 140-151.
25. Holmes DR Jr, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012; 59: 1200-1254.
26. Levison JA, Faust GR, Halpern VJ, et al. Relationship of protamine dosing with postoperative complications of carotid endarterectomy. Ann Vasc Surg. 1999; 13: 67-72.
27. Thompson KA, Philip KJ, Schwarz ER. Clinical applications of bivalirudin in the cardiac catheterization laboratory. J Cardiovasc Pharmacol Ther. 2011; 16: 140-149.
28. Dangas GD, Lefèvre T, Kupatt C. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement. A randomized phase 3 trial. J Am Coll Cardiol. 2015 Oct 8. DOI: 10.1016/j.jacc.2015.10.003. [Epub ahead of print].
29. Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol. 2012; 28: 520-528.
30. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy vs aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011; 108: 1772-1776.
31. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014; 174: 624-627.
32. Poliacikova P, Cockburn J, De Belder A, et al. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation-comparison of regimes. J Invasive Cardiol. 2013; 25: 544-548.
33. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2014; 113: 355-360.
34. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014; 370: 1790-1798.
35. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012; 366: 1696-1704.
36. Nombela-Franco L, Webb JG, De Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012; 126: 3041-3053.
37. Latib A, Messika-Zeitoun D, Maisano F, et al. Reversible Edwards Sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol. 2013; 61: 787-789.
38. Cota L, Stabile E, Agrusta M, et al. Bioprostheses thrombosis after transcatheter aortic valve replacement. J Am Coll Cardiol. 2013; 61: 789-791.
39. Tay ELW, Gurvitch R, Wijeysinghe N, et al. Valve thrombosis after transcatheter heart valve implantation. Eurointervention. 2011; 7: 170-171.
40. Pache G, Schoechlin S, Blanke P. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2015 Oct 7. [Epub ahead of print].
41. Makkar RR, Fontana G, Jilaihawi H. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015-2024.
42. Mok M, Urena M, Nombela-Franco L, et al. Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2013; 35: 450-455.
43. Buchanan GL, Chieffo A, Montorfano M, et al. The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN and Medtronic CoreValve ReValving System(R) devices: the Milan registry. EuroIntervention. 2011; 7: 556-634.
44. Linke A, Bosmans J, Gerkens U. Impact of gender on the outcomes of TAVI: insights from the multicenter ADVANCE study. EuroIntervention. 2012; 8 (Suppl N): 376.
45. Al-Lamee R, Broyd C, Parker J. Influence of gender on clinical outcomes following transcatheter aortic valve implantation from the UK transcatheter aortic valve implantation registry and the National Institute for Cardiovascular Outcomes Research. Am J Cardiol. 2014;113:522-528.
46. Onorati F, DErrigo P, Barbanti M, on behalf of the OBSERVANT Research Group. Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: results of the multicenter Italian OBSERVANT Registry. J Thorac Cardiovasc Surg. 2013;147:1529-1539.
47. Van Mieghem NM, Tchetche D, Chieffo. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol. 2012;110:1361-1367.
48. DAscenzo F, Gonella A, Moretti C. Gender differences in patients undergoing TAVI: a multicentre study. EuroIntervention. 2013; 9: 367-372.
49. Thomas M, Schymik G, Walther T. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2011; 124: 425-433.
50. Buja P, Napodano M, Tamburino C. Italian Multicenter CoreValve Registry I, Comparison of variables in men versus women undergoing transcatheter aortic valve implantation for severe aortic stenosis (from Italian Multicenter CoreValve registry). Am J Cardiol. 2013; 111: 88-93.21.
51. Williams M, Kodali SK, Hahn RT. Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 2014;63:1522-1528.
52. Hayashida K, Morice MC, Chevalier B. Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis. J Am Coll Cardiol. 2012; 59: 566-571.
53. Humphries KH, Toggweiler S, Rodés-Cabau J, et al. Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2012; 60: 882-886.